The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

GLP-1 drugs may result in better outcomes for cancer patients, study claims - GLP-1 drugs, such as Ozempic and Wegovy, may slow down the spread of obesity-related cancers, according to researchers ...

GLP-1 medications were initially developed and prescribed to help manage blood sugar in people with Type 2 diabetes ...

A Cleveland Clinic study finds Ozempic-style GLP-1 drugs may significantly slow the spread of several obesity-related cancers ...

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week ...

Among patients with diabetes who require in-center hemodialysis, the use of GLP-1 receptor agonists is associated with a lower risk of developing Alzheimer disease and related dementias compared with ...

In patients with type 2 diabetes (T2D), dual therapy with metformin and GLP-1 receptor agonists (RAs) was associated with a 39% lower risk for adiposity-related cancers and a 67% lower risk for ...

Significant reductions seen in non-small cell lung cancer, breast cancer, colorectal cancer, and hepatocellular carcinoma.

New data suggest that GLP-1 medication could reduce metastatic progression in certain cancers, according to findings that will be presented at the 2026 American Society of Clinical Oncology’s annual ...

Glucagon-like peptide-1 receptor agonists vs alternative therapies are not associated with increased risk for suicide and may lower risk.

A Cleveland Clinic study suggests GLP-1 weight loss drugs may help slow the spread of some obesity-related cancers.